Co-development partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal.
The global market for Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics by region & country, by Type, and by Application.
The Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics.
麻豆原创 Segmentation
By Company
1ST Biotherapeutics
3B Pharmaceuticals
3D-Micromac
3DMed
3D Systems
10X Genomics
A*STAR Agency for Science
Technology and Research
A*STAR Institute of Microelectronics (IME)
A2A Pharmaceuticals
Abbvie
AbCellera
ABL Bio
Abpro
Academy of Military Medical Sciences (China)
Accellix
Accord Healthcare
AccuGenomics
ACEA Biosciences
AC Immune
Acoustic MedSystems
Adaptimmune
Aduro BioTech
Advaxis
Adventus Ventures
Aerolase
Segment by Type:
Asset purchase
Assignment
Co-development
Co-market
Co-promotion
Collaborative R&D
Contract service
CRADA
Cross-licensing
Others
Segment by Application
Industry sector
Therapy areas
Technology type
Deal components
Financial terms
Stage of development
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 麻豆原创 Overview
1.1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Introduction
1.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Size Forecast
1.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Trends & Drivers
1.3.1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Industry Trends
1.3.2 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Drivers & Opportunity
1.3.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Challenges
1.3.4 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Players Revenue Ranking (2023)
2.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue by Company (2019-2024)
2.3 Key Companies Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Manufacturing Base Distribution and Headquarters
2.4 Key Companies Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offered
2.5 Key Companies Time to Begin Mass Production of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
2.6 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Competitive Analysis
2.6.1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Asset purchase
3.1.2 Assignment
3.1.3 Co-development
3.1.4 Co-market
3.1.5 Co-promotion
3.1.6 Collaborative R&D
3.1.7 Contract service
3.1.8 CRADA
3.1.9 Cross-licensing
3.1.10 Others
3.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Type
3.2.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value, by Type (2019-2030)
3.2.3 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Industry sector
4.1.2 Therapy areas
4.1.3 Technology type
4.1.4 Deal components
4.1.5 Financial terms
4.1.6 Stage of development
4.1.7 Others
4.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Application
4.2.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value, by Application (2019-2030)
4.2.3 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Region
5.1.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Region (2019-2024)
5.1.3 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Region (2025-2030)
5.1.4 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value, 2019-2030
5.2.2 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value, 2019-2030
5.3.2 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value, 2019-2030
5.4.2 Asia Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value, 2019-2030
5.5.2 South America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value, 2019-2030
5.6.2 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value
6.3 United States
6.3.1 United States Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value, 2019-2030
6.3.2 United States Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value, 2019-2030
6.4.2 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value, 2019-2030
6.5.2 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Type (%), 2023 VS 2030
6.5.3 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value, 2019-2030
6.6.2 Japan Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value, 2019-2030
6.7.2 South Korea Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value, 2019-2030
6.8.2 Southeast Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value, 2019-2030
6.9.2 India Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Type (%), 2023 VS 2030
6.9.3 India Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 1ST Biotherapeutics
7.1.1 1ST Biotherapeutics Profile
7.1.2 1ST Biotherapeutics Main Business
7.1.3 1ST Biotherapeutics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Products, Services and Solutions
7.1.4 1ST Biotherapeutics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$ Million) & (2019-2024)
7.1.5 1ST Biotherapeutics Recent Developments
7.2 3B Pharmaceuticals
7.2.1 3B Pharmaceuticals Profile
7.2.2 3B Pharmaceuticals Main Business
7.2.3 3B Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Products, Services and Solutions
7.2.4 3B Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$ Million) & (2019-2024)
7.2.5 3B Pharmaceuticals Recent Developments
7.3 3D-Micromac
7.3.1 3D-Micromac Profile
7.3.2 3D-Micromac Main Business
7.3.3 3D-Micromac Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Products, Services and Solutions
7.3.4 3D-Micromac Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$ Million) & (2019-2024)
7.3.5 3DMed Recent Developments
7.4 3DMed
7.4.1 3DMed Profile
7.4.2 3DMed Main Business
7.4.3 3DMed Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Products, Services and Solutions
7.4.4 3DMed Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$ Million) & (2019-2024)
7.4.5 3DMed Recent Developments
7.5 3D Systems
7.5.1 3D Systems Profile
7.5.2 3D Systems Main Business
7.5.3 3D Systems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Products, Services and Solutions
7.5.4 3D Systems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$ Million) & (2019-2024)
7.5.5 3D Systems Recent Developments
7.6 10X Genomics
7.6.1 10X Genomics Profile
7.6.2 10X Genomics Main Business
7.6.3 10X Genomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Products, Services and Solutions
7.6.4 10X Genomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$ Million) & (2019-2024)
7.6.5 10X Genomics Recent Developments
7.7 A*STAR Agency for Science
7.7.1 A*STAR Agency for Science Profile
7.7.2 A*STAR Agency for Science Main Business
7.7.3 A*STAR Agency for Science Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Products, Services and Solutions
7.7.4 A*STAR Agency for Science Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$ Million) & (2019-2024)
7.7.5 A*STAR Agency for Science Recent Developments
7.8 Technology and Research
7.8.1 Technology and Research Profile
7.8.2 Technology and Research Main Business
7.8.3 Technology and Research Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Products, Services and Solutions
7.8.4 Technology and Research Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$ Million) & (2019-2024)
7.8.5 Technology and Research Recent Developments
7.9 A*STAR Institute of Microelectronics (IME)
7.9.1 A*STAR Institute of Microelectronics (IME) Profile
7.9.2 A*STAR Institute of Microelectronics (IME) Main Business
7.9.3 A*STAR Institute of Microelectronics (IME) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Products, Services and Solutions
7.9.4 A*STAR Institute of Microelectronics (IME) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$ Million) & (2019-2024)
7.9.5 A*STAR Institute of Microelectronics (IME) Recent Developments
7.10 A2A Pharmaceuticals
7.10.1 A2A Pharmaceuticals Profile
7.10.2 A2A Pharmaceuticals Main Business
7.10.3 A2A Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Products, Services and Solutions
7.10.4 A2A Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$ Million) & (2019-2024)
7.10.5 A2A Pharmaceuticals Recent Developments
7.11 Abbvie
7.11.1 Abbvie Profile
7.11.2 Abbvie Main Business
7.11.3 Abbvie Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Products, Services and Solutions
7.11.4 Abbvie Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$ Million) & (2019-2024)
7.11.5 Abbvie Recent Developments
7.12 AbCellera
7.12.1 AbCellera Profile
7.12.2 AbCellera Main Business
7.12.3 AbCellera Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Products, Services and Solutions
7.12.4 AbCellera Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$ Million) & (2019-2024)
7.12.5 AbCellera Recent Developments
7.13 ABL Bio
7.13.1 ABL Bio Profile
7.13.2 ABL Bio Main Business
7.13.3 ABL Bio Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Products, Services and Solutions
7.13.4 ABL Bio Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$ Million) & (2019-2024)
7.13.5 ABL Bio Recent Developments
7.14 Abpro
7.14.1 Abpro Profile
7.14.2 Abpro Main Business
7.14.3 Abpro Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Products, Services and Solutions
7.14.4 Abpro Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$ Million) & (2019-2024)
7.14.5 Abpro Recent Developments
7.15 Academy of Military Medical Sciences (China)
7.15.1 Academy of Military Medical Sciences (China) Profile
7.15.2 Academy of Military Medical Sciences (China) Main Business
7.15.3 Academy of Military Medical Sciences (China) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Products, Services and Solutions
7.15.4 Academy of Military Medical Sciences (China) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$ Million) & (2019-2024)
7.15.5 Academy of Military Medical Sciences (China) Recent Developments
7.16 Accellix
7.16.1 Accellix Profile
7.16.2 Accellix Main Business
7.16.3 Accellix Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Products, Services and Solutions
7.16.4 Accellix Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$ Million) & (2019-2024)
7.16.5 Accellix Recent Developments
7.17 Accord Healthcare
7.17.1 Accord Healthcare Profile
7.17.2 Accord Healthcare Main Business
7.17.3 Accord Healthcare Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Products, Services and Solutions
7.17.4 Accord Healthcare Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$ Million) & (2019-2024)
7.17.5 Accord Healthcare Recent Developments
7.18 AccuGenomics
7.18.1 AccuGenomics Profile
7.18.2 AccuGenomics Main Business
7.18.3 AccuGenomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Products, Services and Solutions
7.18.4 AccuGenomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$ Million) & (2019-2024)
7.18.5 AccuGenomics Recent Developments
7.19 ACEA Biosciences
7.19.1 ACEA Biosciences Profile
7.19.2 ACEA Biosciences Main Business
7.19.3 ACEA Biosciences Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Products, Services and Solutions
7.19.4 ACEA Biosciences Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$ Million) & (2019-2024)
7.19.5 ACEA Biosciences Recent Developments
7.20 AC Immune
7.20.1 AC Immune Profile
7.20.2 AC Immune Main Business
7.20.3 AC Immune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Products, Services and Solutions
7.20.4 AC Immune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$ Million) & (2019-2024)
7.20.5 AC Immune Recent Developments
7.21 Acoustic MedSystems
7.21.1 Acoustic MedSystems Profile
7.21.2 Acoustic MedSystems Main Business
7.21.3 Acoustic MedSystems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Products, Services and Solutions
7.21.4 Acoustic MedSystems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$ Million) & (2019-2024)
7.21.5 Acoustic MedSystems Recent Developments
7.22 Adaptimmune
7.22.1 Adaptimmune Profile
7.22.2 Adaptimmune Main Business
7.22.3 Adaptimmune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Products, Services and Solutions
7.22.4 Adaptimmune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$ Million) & (2019-2024)
7.22.5 Adaptimmune Recent Developments
7.23 Aduro BioTech
7.23.1 Aduro BioTech Profile
7.23.2 Aduro BioTech Main Business
7.23.3 Aduro BioTech Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Products, Services and Solutions
7.23.4 Aduro BioTech Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$ Million) & (2019-2024)
7.23.5 Aduro BioTech Recent Developments
7.24 Advaxis
7.24.1 Advaxis Profile
7.24.2 Advaxis Main Business
7.24.3 Advaxis Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Products, Services and Solutions
7.24.4 Advaxis Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$ Million) & (2019-2024)
7.24.5 Advaxis Recent Developments
7.25 Adventus Ventures
7.25.1 Adventus Ventures Profile
7.25.2 Adventus Ventures Main Business
7.25.3 Adventus Ventures Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Products, Services and Solutions
7.25.4 Adventus Ventures Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$ Million) & (2019-2024)
7.25.5 Adventus Ventures Recent Developments
7.26 Aerolase
7.26.1 Aerolase Profile
7.26.2 Aerolase Main Business
7.26.3 Aerolase Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Products, Services and Solutions
7.26.4 Aerolase Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (US$ Million) & (2019-2024)
7.26.5 Aerolase Recent Developments
8 Industry Chain Analysis
8.1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Industrial Chain
8.2 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Sales Model
8.5.2 Sales Channel
8.5.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
1ST Biotherapeutics
3B Pharmaceuticals
3D-Micromac
3DMed
3D Systems
10X Genomics
A*STAR Agency for Science
Technology and Research
A*STAR Institute of Microelectronics (IME)
A2A Pharmaceuticals
Abbvie
AbCellera
ABL Bio
Abpro
Academy of Military Medical Sciences (China)
Accellix
Accord Healthcare
AccuGenomics
ACEA Biosciences
AC Immune
Acoustic MedSystems
Adaptimmune
Aduro BioTech
Advaxis
Adventus Ventures
Aerolase
听
听
*If Applicable.
